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Abstract We found that prostaglandin (PG) D2 and PGE2,
which are major PGs in the brain of mammals, powerfully in-
duced the secretion of nerve growth factor (NGF) from cultured
mouse astrocytes; PGE2 or PGD2 induced an approximately
12- or 19-fold increase in NGF secretion after a 24-h incuba-
tion, respectively. Moreover, it was found that the sequential
metabolites of PGD2, PGJ2, v12-PGJ2, and 15-deoxy-v12;14-
PGJ2, induced the NGF secretion to the culture medium strik-
ingly (60^98-fold of the control after a 24-h incubation). NGF
secretion induced by the J2 series of PGs was accompanied by
the increased expression of NGF mRNA. These PGs also stimu-
lated the secretion/synthesis of brain-derived neurotrophic factor
(BDNF). Our ¢ndings suggest that PGs play a neuroprotective
role by inducing NGF and BDNF production in the central
nervous system.
9 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Prostaglandins (PGs) are the major lipid mediators pro-
duced by cyclooxygenase activity, and they play important
modulatory roles in various cells throughout the whole
body. In the central nervous system (CNS), PGs and other
bioactive lipids regulate various vital aspects of neural mem-
brane biology, including protein^lipid interactions as well as
trans-membrane and trans-synaptic signalings [1]. Some cur-
rent reports raised a possibility that brain PGs are key players
at the early stages of acute neural trauma and brain-cell dam-
age associated with chronic neurodegenerative diseases such
as Alzheimer’s disease (AD) [2,3].
Nerve growth factor (NGF) is well known to be essential to
preserve the cholinergic neurons of the basal nucleus of Mey-
nert in culture, and it has been considered a potential thera-
peutic agent for the treatment of AD [4,5]. Brain-derived neu-
rotrophic factor (BDNF) has clear neurorestorative and
neuroprotective e¡ects on dopaminergic neurons [6^8], and
it is considered to contribute to neuroprotection in Parkin-
son’s disease.
However, the e¡ects of PGs on the production of neuro-
trophins have not yet been de¢ned. Therefore, we investigated
the e¡ects of PGs on the synthesis/secretion of the above-
mentioned neurotrophins by cultured mouse astrocytes.
2. Materials and methods
2.1. Materials
Anti-mouse L-NGF monoclonal antibody and anti-BDNF mono-
clonal antibody were purchased from Roche Molecular Biochemicals
(Mannheim, Germany) and RpD systems (Minneapolis, MN, USA),
respectively. Human recombinant BDNF and anti-BDNF polyclonal
antibody were from Promega (Madison, WI, USA). PGF2K, PGI2,
PGE2, PGD2, PGA2, PGB2, PGJ2, v12-PGJ2, and 15-deoxy-
v12;14PGJ2 (15d-PGJ2) were from Cayman (Ann Arbor, MI, USA).
Lipopolysaccharide (LPS) was obtained from Sigma-Aldrich (St.
Louis, MO, USA).
2.2. Astrocyte culture
Cortical astrocytes were derived from 2-day-old mice (ICR) as de-
scribed previously [9] with minor modi¢cations. After removal of the
meninges, the cerebral cortex was cut into small pieces, and washed in
Leibowitz L-15 medium. The pieces were then treated with 0.25%
trypsin at 37‡C for 25 min. After the trypsin had been neutralized
in Dulbecco’s modi¢ed Eagle’s medium (DMEM; Sigma-Aldrich)
containing 10% fetal bovine serum (FBS; BioWhittaker, Walkersville,
MD, USA) and penicillin^streptomycin solution, the cells were rinsed
and seeded into 25-cm2 tissue culture £asks. The culture became al-
most con£uent 4^5 days after the seeding, and the cells were then
trypsinized and recultured in new £asks. This procedure was repeated
twice. Finally, the cells were seeded at a density of 105 cells/cm2 in 48-
well plates or in 6-cm dishes. The con£uent cells were exposed for
about 10 days to FBS-free DMEM containing 0.5% bovine serum
albumin, and then incubated with di¡erent concentrations of PGs
for 24 h. Finally, the culture medium and cells were separately col-
lected and used for the measurement of neurotrophin content.
2.3. Enzyme immunoassay of NGF
NGF content in the cell supernatant was measured by using a
sensitive two-site enzyme-linked immunosorbent assay (ELISA) sys-
tem as previously described [10] with slight modi¢cations. Brie£y,
polystyrene microtiter plates (Corning, Corning, NY, USA) were
coated for 1 h at room temperature with 50 Wl of 0.2 Wg/ml anti-L-
NGF monoclonal antibody that had been diluted with 10 mM sodium
carbonate^bicarbonate bu¡er, pH 9.3. After the plates had been
washed three times with washing bu¡er (50 mM Tris^HCl, 200 mM
NaCl, 10 mM CaCl2, 0.1% Triton X-100; pH 7.0), non-speci¢c bind-
ing sites were saturated with 10% Block Ace (Dainippon Pharmaceu-
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tical, Osaka, Japan), and the plates were then washed three times
again with the bu¡er. Subsequently, 50 Wl sample or L-NGF standard
solution was added to each well of the plates, which were then incu-
bated overnight at 4‡C. Each well was next washed three times with
the washing bu¡er, 50 Wl of biotinylated anti-L-NGF monoclonal
antibody conjugate was added, and incubation was continued for 1 h
at 37‡C. After the plates had been washed again three times, strep-
tavidin-linked horseradish peroxidase (HRP) (Amgen, Thousand
Oaks, CA, USA) was added to each well; then incubation was done
for 1 h at room temperature, followed by ¢ve washes. The enzyme
reaction was started by the addition of 100 Wl of TMB-H2O2 solution
(Kirkegaard and Perry, Gaithersburg, MD, USA), and stopped by the
addition of 100 Wl of 1 M H3PO4. The absorbance of the plates was
read at a wavelength of 450 nm.
2.4. Enzyme immunoassay of BDNF
BDNF content in the cell supernatant was measured by the method
described previously [11] with slight modi¢cations. Brie£y, the micro-
titer plates were coated with 50 Wl of 1 Wg/ml anti-BDNF monoclonal
antibody. Human recombinant BDNF was used as a standard solu-
tion. Anti-BDNF polyclonal antibody was biotinylated for use as the
secondary antibody. The bound antibody complex was measured with
streptavidin-linked HRP by a method similar to that for NGF.
2.5. Semi-quantitative polymerase chain reaction (PCR)
After treatment of the astrocyte cultures with PGs for a desired
period of time, the total RNA of the cells was extracted by using
an RNeasy RNA extraction kit (Qiagen, Valencia, CA, USA), and
then treated with DNase I (Invitrogen, San Diego, CA, USA). Re-
verse transcription (RT) was carried out with a Transcription Kit
(Invitrogen). Aliquots of the cDNA were ampli¢ed in 25 Wl of PCR
cocktail containing each speci¢c primer and KOD Dash DNA poly-
merase (Toyobo, Osaka, Japan). Glyceraldehyde-3-phosphate dehy-
drogenase (G3PDH) transcripts were used as a positive control. Based
on the preliminary experiments conducted to establish the optimal
conditions for the ampli¢cation of each primer pair, the target cDNAs
of NGF, BDNF, and G3PDH cDNA were ampli¢ed for 32, 31, and
26 cycles, respectively. The following primer pairs were used: for
NGF, 5P-AGTGAACATGCTGTGCCTCAAGCC-3P (sense) and 5P-
GGCAAGTCAGCCTCTTCTTGTAGC-3P (antisense); for BDNF,
5P-AGGTGAGAAGAGTGATGACCATCC-3P (sense) and 5P-CAA-
CATAAATCCACTATCTTCCCC-3P (antisense); and for G3PDH,
5P-TGAAGGTCGGTGTGAACGGATTTGGC-3P (sense) and 5P-
CATGTAGGCCATGAGGTCCACCAC-3P (antisense). The expected
product sizes were 937 bp for NGF, 777 bp for BDNF, and 983 bp
for G3PDH. The PCR products were electrophoresed on an agarose
gel containing ethidium bromide, and photographed under UV light.
Intensity of the ampli¢ed bands was analyzed by using Scion Image
software.
2.6. Statistical analysis
Data are presented as meanSS.D. Signi¢cance was determined us-
ing one-way analysis of variance followed by a post-hoc test with
statistical analysis software (SPSS, LEAD Technologies).
3. Results
We examined the e¡ects of various natural PGs on the
NGF secretion from cultured mouse astrocytes by ELISA.
Fig. 1 shows the biosynthetic pathways of the PGs used. As
shown in Fig. 2, PGF2K and PGI2 slightly stimulated the
NGF secretion, whereas PGE2 and PGD2 stimulated it sig-
ni¢cantly. Galve-Roperh et al. reported that some lipid medi-
ators such as ceramide [12] and LPS [13] stimulated NGF
secretion from cultured astrocytes. They indicated the maxi-
mum level of NGF secretion after 24 h of treatment with
25 WM C2-ceramide or 2 Wg/ml LPS to be nine- or eight-
fold, respectively, of the control. In our cultures, LPS simi-
larly stimulated NGF secretion, and the maximum levels of
NGF secretion elicited by 0.5 Wg/ml LPS were about seven-
fold of the control after 24 h (Fig. 1). In this study, the
maximum level of NGF secretion stimulated by PGE2 or
PGD2 treatment was two- or seven-fold greater than the max-
imum level obtained with LPS.
PGE2 is known to rapidly undergo non-enzymatic dehydra-
tion in culture medium containing serum albumin to produce
PGA2 [14] ; and under alkaline conditions, PGE2 and PGA2
are degraded to PGB2 [15]. So, we examined also the e¡ects of
PGA2 and PGB2. PGA2 had a greater e¡ect on NGF secre-
tion from astrocytes than PGE2, whereas PGB2 had a weaker
e¡ect than PGE2 (Fig. 3A). On the other hand, PGs of the J2
series (PGJ2, v12-PGJ2, and 15d-PGJ2), naturally occurring
derivatives of PGD2 [16^18], showed a dramatically greater
e¡ect than PGD2 on the NGF secretion from cultured astro-
cytes. As shown in Fig. 3B, PGD2 induced an approximately
19-fold increase in NGF secretion, while PGJ2 (30 WM), v12-
PGJ2 (20 WM), and 15d-PGJ2 (75 WM) caused an increase up
to higher levels of 60-, 74-, and 98-fold, respectively, of the
control.
To examine whether the stimulatory e¡ects of PGD2 and its
metabolites on NGF secretion were accompanied by de novo
synthesis of NGF protein, we determined the time dependence
of their e¡ects on NGF mRNA expression. Total RNA from
the astrocytes treated with PGD2, PGJ2, v12-PGJ2, or 15d-
PGJ2 was analyzed by the RT-PCR method. As shown in Fig.
4, NGF mRNA expression began to be induced 3 h after the
addition of these PGs and did not return to the basal level
even after 48 h. The e¡ects of PGD2 and its metabolites on
the NGF synthesis/secretion in cultured astrocytes were thus
long-lasting.
BDNF mRNA expression level was also investigated, and
we found that PGD2 and its metabolites stimulated the ex-
pression of BDNF mRNA as well. Fig. 4B shows time courses
of the level of BDNF mRNA after treatment of PGD2 and its
metabolites. The maximum levels of the BDNF mRNA were
2^2.8-fold of the control at around 12 h after the start of
treatment with the PGs, and after 24 h they returned to the
basal level almost completely. Unlike the case of NGF syn-
Fig. 1. The prostaglandin biosynthetic pathway. Arachidonic acid is
¢rst converted to the central prostanoid precursor PGH2 via the ac-
tion of the bifunctional enzyme PGH synthetase. PGH2 is then con-
verted to one of several related products, including PGD2, PGE2,
PGF2K, and PGI2, through the action of speci¢c PG synthetases.
PGD2 readily undergoes dehydration non-enzymatically to yield
PGJ2. PGJ2 is further converted to v12-PGJ2 or 15d-PGJ2 ; the for-
mation of the former from PGJ2 is accelerated by serum albumin.
PGA2 is the dehydration product of PGE2, and under alkaline con-
ditions, PGE2 and PGA2 are degraded to PGB2.
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thesis, the BDNF synthesis induced by PGD2 and its metab-
olites seemed to be comparatively transient. The amount of
BDNF secreted into the culture medium was also examined.
As shown in Fig. 5, even at 12 h after the start of treatment
with these PGs, it was found that the BDNF secretion was
stimulated, although the level of stimulation was lower than
that for NGF. These levels of NGF and BDNF secretion are
in good agreement with those of mRNA expression shown in
Fig. 4.
4. Discussion
PGs are regarded as modulators of cellular functions in
various physiological processes. As PGs have various func-
tions in the CNS, they have recently been considered to serve
as mediators of glial and neuronal functions [19,20].
Here we showed that several natural PGs induced NGF
secretion markedly. The result suggests that PGs in the
CNS act as potent inducers of NGF and thus would have
neuroprotective e¡ects. Especially, PGD2 metabolites, i.e. cy-
clopentenone PGs of the J2 series, stimulated the NGF secre-
tion/synthesis quite potently and persistently. Also, these PGs
stimulated the secretion/synthesis of BDNF in cultured astro-
cytes as well, although the levels were lower than those for
NGF, and the stimulatory e¡ect was comparatively transient.
These di¡erences in stimulation degree and term between
NGF and BDNF may be due to some di¡erence in the mech-
anisms for up-regulation by these PGs between these two
neurotrophins.
It has been reported that PGD2 is spontaneously dehy-
drated in aqueous solutions to yield PGJ2 [16,17]. PGJ2 is
further converted to 15d-PGJ2 in an albumin-independent
manner or, alternatively, to v12-PGJ2 in an albumin-depen-
dent manner [18]. PGE2 is also known to be rapidly dehy-
drated to PGA2 in culture medium containing serum albumin
[14]. Actually, when PGD2 or PGE2 was incubated overnight
Fig. 2. E¡ects of PGs and LPS on the NGF secretion from mouse astrocytes. The cells were incubated with the indicated concentrations of
PGs or LPS for 24 h. Results are the meanSS.D. of three independent experiments. Statistically di¡erent data are indicated by asterisks
(P6 0.05).
Fig. 3. E¡ects of PGE2 and PGD2 metabolites on the NGF secretion from mouse astrocytes. The cells were incubated with di¡erent concentra-
tions of PGs for 24 h. A: PGE2 (b) and its metabolites, PGA2 (R) and PGB2 (a). B: PGD2 (b) and its metabolites, PGJ2 (R), v12-PGJ2
(E), and 15d-PGJ2 (a). Results are the meanSS.D. of three independent experiments.
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in our culture medium, we observed by thin-layer chromatog-
raphy that almost all PGD2 was converted to the J2 series of
PGs, and almost all PGE2 to PGA2. The J2 series of PGs
showed a dramatically greater e¡ect on NGF secretion than
PGD2. Likewise, PGA2 showed a greater e¡ect than PGE2.
Therefore, the e¡ect of PGD2 or PGE2 is likely to be medi-
ated by their respective metabolic products.
At any rate, PGD2 and its metabolites were found to be
inducers of NGF and BDNF in cultured mouse astrocytes.
PGD2 is one of the most abundant PGs produced in the brain
[21,22], and acts to induce physiological sleep [23^26]. As
described above, PGD2 is readily dehydrated to produce
PGJ2 and metabolized further to yield v12-PGJ2 or 15d-
PGJ2. It is clear that PGD2 is converted to its metabolites
in vivo as well as in vitro [18]. Consequently, it is conceivable
that PGD2 synthesized by PGD2 synthase not only promotes
sleep, but also, through its metabolism, may act on astrocytes
in brain to stimulate potently the production of neurotro-
phins. It is known that neurotrophins not only prevent neuro-
nal death but also promote regeneration of neural networks in
the CNS. This hypothesis should provoke further research as
to the roles of PGD2, the most abundant prostanoid in the
CNS. A variety of brain cells such as astrocytes, microglial
cells, and neurons can synthesize PGs [27^29]. Since these PGs
may have autocrine/paracrine actions, PGs produced in the
brain may induce the synthesis of neurotrophins in astrocytes.
It has already been reported that LPS is an inducer of NGF
secretion from astrocytes. But the details of the mechanism
are not clear. On the other hand, it has been reported that
LPS stimulates the release of PGE2 from astrocytes in culture
[30]. As we found in this study that PGE2 stimulated NGF
secretion from astrocytes, the e¡ect of LPS on NGF secretion
may be through the production of PGE2 stimulated by the
LPS treatment.
Recently, the association of low BDNF levels with major
depressive disorders was suggested [31^33]. In animals sub-
jected to forced swimming [34] or chronic immobilization
stress [35,36], BDNF mRNA levels were signi¢cantly sup-
pressed. Moreover, it was reported that the reduced BDNF
levels in depressed patients recovered to basal levels after anti-
depressant treatment [37]. Our experiments revealed that
PGD2 and its metabolites stimulated the BDNF secretion/syn-
thesis by mouse astrocytes. This is suggestive of correlation
between depression and these PGs in the brain.
Fig. 4. E¡ects of PGD2 and its metabolites on the mRNA levels of NGF, BDNF, and G3PDH. A: Total RNA from untreated astrocytes (0 h)
or from those treated with 100 WM PGD2, 30 WM PGJ2, 20 WM v12-PGJ2, or 75 WM 15d-PGJ2 for 3, 6, 12, 24, and 48 h was analyzed by the
RT-PCR method. B: Time course of the mRNA expressions of NGF (left) and BDNF (right). The NGF, BDNF, and G3PDH intensities rela-
tive to those of control were calculated, and the ratios (relative NGF)/(relative G3PDH) and (relative BDNF)/(relative G3PDH) were used to
indicate the relative amounts of NGF and BDNF gene expression, respectively. b, PGD2 ; R, PGJ2 ; E, v12-PGJ2 ; a, 15d-PGJ2. Similar results
were obtained in two independent experiments.
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In conclusion, it is now certain that several natural PGs are
powerful inducers of NGF and BDNF production in cultured
mouse astrocytes. This fact suggests that PGs in the CNS may
act neuroprotectively to induce the production/release of these
neurotrophins by astrocytes.
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Fig. 5. The secretion levels of NGF and BDNF from mouse
astrocytes after a 12-h incubation with PGD2 and its metabolites.
The cells were incubated for 12 h with 100 WM PGD2, 30 WM
PGJ2, 20 WM v12-PGJ2, or 75 WM 15d-PGJ2. NGF content (open
bars) and BDNF content (solid bars) in the medium were measured
by speci¢c immunoassays as described in Section 2. Results are
meanSS.D. of two experiments. Statistically di¡erent data are indi-
cated by asterisks (P6 0.05).
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